Evidence map›Paper›PMID 38265371›Full record

ReviewPharmaceutical nanotechnology2025

Core-Shell Nanoparticles for Pulmonary Drug Delivery.

Mukesh P Ratnaparkhi, Shailendra S Salvankar, Avinash R Tekade, Gajanan M Kulkarni

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmaceutical nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mukesh P RatnaparkhiDepartment of Pharmaceutics, Marathwada Mitra Mandal's College of Pharmacy, Thergaon, Pune, Maharashtra, 411033, India.ORCID 0000-0003-0446-4243
Shailendra S SalvankarDepartment of Pharmaceutics, Marathwada Mitra Mandal's College of Pharmacy, Thergaon, Pune, Maharashtra, 411033, India.ORCID 0000-0001-5612-7017
Avinash R TekadeDepartment of Pharmaceutics, Marathwada Mitra Mandal's College of Pharmacy, Thergaon, Pune, Maharashtra, 411033, India.ORCID 0000-0001-8564-1859
Gajanan M KulkarniDepartment of Pharmaceutics, Marathwada Mitra Mandal's College of Pharmacy, Thergaon, Pune, Maharashtra, 411033, India.ORCID 0000-0002-6593-1928

Funding

RPS AICTE, All India Council for Technical Education, New Delhi 8-129/FDC/RPS/Policy-I/2021-22
6 · The paper itself

Abstract

Nanoscale drug delivery systems have provoked interest for application in various therapies on account of their ability to elevate the intracellular concentration of drugs inside target cells, which leads to an increase in efficacy, a decrease in dose, and dose-associated adverse effects. There are several types of nanoparticles available; however, core-shell nanoparticles outperform bare nanoparticles in terms of their reduced cytotoxicity, high dispersibility and biocompatibility, and improved conjugation with drugs and biomolecules because of better surface characteristics. These nanoparticulate drug delivery systems are used for targeting a number of organs, such as the colon, brain, lung, etc. Pulmonary administration of medicines is a more appealing method as it is a noninvasive route for systemic and locally acting drugs as the pulmonary region has a wide surface area, delicate blood-alveolar barrier, and significant vascularization. A core-shell nano-particulate drug delivery system is more effective in the treatment of various pulmonary disorders. Thus, this review has discussed the potential of several types of core-shell nanoparticles in treating various diseases and synthesis methods of core-shell nanoparticles. The methods for synthesis of core-shell nanoparticles include solid phase reaction, liquid phase reaction, gas phase reaction, mechanical mixing, microwave- assisted synthesis, sono-synthesis, and non-thermal plasma technology. The basic types of core-shell nanoparticles are metallic, magnetic, polymeric, silica, upconversion, and carbon nanomaterial- based core-shell nanoparticles. With this special platform, it is possible to integrate the benefits of both core and shell materials, such as strong serum stability, effective drug loading, adjustable particle size, and immunocompatibility.

Indexed as

Drug Delivery SystemsLungLung DiseasesNanoparticle Drug Delivery SystemNanoparticlesAdministration, InhalationAnimalsDrug CarriersHumansDrug CarriersNanoparticle Drug Delivery Systemcore-shell nanoparticleslung cancerNanoparticlesnon-invasive therapypulmonary deliveryrespiratory diseases.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.